Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study-Reference-Cited by-同舟云学术

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Published:2017-02-16 Issue:7 Volume:129 Page:846-854
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rea Delphine¹,Nicolini Franck E.²,Tulliez Michel³,Guilhot François⁴,Guilhot Joelle⁴,Guerci-Bresler Agnès⁵,Gardembas Martine⁶,Coiteux Valérie⁷,Guillerm Gaelle⁸,Legros Laurence⁹,Etienne Gabriel¹⁰,Pignon Jean-Michel¹¹,Villemagne Bruno¹²,Escoffre-Barbe Martine¹³,Ianotto Jean-Christophe⁸,Charbonnier Aude¹⁴,Johnson-Ansah Hyacinthe¹⁵,Noel Marie-Pierre⁷,Rousselot Philippe¹⁶,Mahon François-Xavier¹⁰,

Affiliation:

1. Service d’Hématologie Adulte and INSERM UMRS-1160, Hôpital Saint-Louis, Paris, France;

2. Service d'Hématologie Clinique, CHU Lyon Sud, Pierre Bénite and INSERM 1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France;

3. Laboratoire d’Hématologie, CHU Henri Mondor, Créteil, France;

4. INSERM CIC 1402, CHU de Poitiers, France;

5. Service d’Hématologie, CHU Brabois, Vandoeuvre les Nancy, France;

6. Service des Maladies du Sang, CHRU d’Angers, France;

7. Service des Maladies du Sang, Hôpital Huriez, CHRU de Lille, France;

8. Service d’Hématologie Clinique, Hôpital Morvan, CHRU de Brest, France;

9. Service d'Hématologie Clinique, Hôpital de l'Archet, CHU de Nice, France;

10. Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Bordeaux, France;

11. Service d'Hématologie, Centre Hospitalier de Dunkerque, France;

12. Service de Médecine Onco-Hématologie, Centre Hospitalier Départemental Vendée, La Roche sur Yon, France;

13. Service d'Hématologie Adulte, CHU de Rennes, France;

14. Service d’Onco-Hématologie, Institut Paoli Calmettes, Marseille, France;

15. Service d’Hématologie Clinique, CHU de Caen, France; and

16. Service d’Hématologie Oncologie et INSERM UMR-1173, Centre Hospitalier de Versailles, Le Chesnay, France

Abstract

Key Points First-line or subsequent dasatinib or nilotinib can be safely stopped in CML patients with deep and long-lasting molecular responses. A suboptimal response or resistance prior to dasatinib or nilotinib is associated with significantly worse treatment-free remission.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/7/846/1402375/blood742205.pdf

Reference47 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

3. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials;Roy;Blood,2006

4. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib;Gambacorti-Passerini;J Natl Cancer Inst,2011

5. Chronic myeloid leukemia: reminiscences and dreams;Mughal;Haematologica,2016

Cited by 266 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data;Cancer Medicine;2024-09

2. The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemia;2024-08-18

3. Insights into existing and futuristic treatment approach for chronic myeloid leukaemia;Indian Journal of Medical Research;2024-08-03

4. Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment;Clinics and Practice;2024-06-21